Tyra Biosciences Q1 net loss $11.9M, cash $241.7M; programs advance

Tyra Biosciences, Inc.

2023-Q1 EPS reported -$0.28

Net loss $11.9M vs $14.8M YoY; R&D expense $10.4M, G&A $3.9M.
Cash and equivalents $241.7M, expected to fund operations >2 years.
SURF301 Phase 1/2 of TYRA-300 for FGFR3+ tumors continues enrolling patients.
TYRA-300 development expanded into achondroplasia; IND submission targeted in 2024.
TYRA-200 IND cleared by FDA; Phase 1 for cholangiocarcinoma on track for 2H 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Tyra Biosciences, Inc. reported the quarter ended March 31, 2023 results: net income $11.9 million.

Period: the quarter ended March 31, 2023
Net income: $11.9 million
Result: reported results

Exact text from the filing

Tyra Biosciences, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2023.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Tyra Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-017846

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.